Dublin, Feb. 27, 2018 -- The "Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The global point-of-care diagnostics market is projected to reach USD 38.13 Billion by 2022 from USD 23.71 Billion in 2017, at a CAGR of 10.0% during the forecast period.
Factors such as high prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and rising preference for home healthcare across the globe are increasing the adoption of POC diagnostic products globally.
This report broadly segments the rapid diagnostic market into product, platform, mode, end user, and region.
The report covers the point-of-care diagnostics market across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the market in 2017, due to the growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives in this region.
The major players of the market
- Abbott Laboratories
- Accubiotech
- Becton, Dickinson, and Company (BD)
- Chembio Diagnostics
- Danaher Corporation
- EKF Diagnostics
- Instrumentation Laboratory (A Werfen Company)
- Johnson & Johnson
- Nova Biomedical
- PTS Diagnostics (A Part of Sinocare Inc.)
- Quidel
- Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.)
- Sekisui Diagnostics
- Siemens
- Trinity Biotech
Market Dynamics
Drivers
- High Prevalence of Infectious Diseases in Developing Countries
- Increasing Incidence of Target Diseases
- Rising Usage of Home-Based POC Devices
- Growing Government Support
- Technological Advancements and New Product Launches
- Growing Number of Regulatory Approvals for Novel Immunoassay Techniques
- Shortage of Skilled Laboratory Technicians
- Rising Number of Clia-Waived POC Tests
Restraints
- Product Recalls: Hampering User Confidence
- Pricing Pressure Owing to Reimbursement Cuts and Budget Constraints
- Stringent and Time-Consuming Regulatory Policies are Significantly Increasing Gestation Period for Product Launches
Opportunities
- Growth Opportunities in Emerging Markets
- Healthcare Decentralization - Converting Lab Tests to POC Tests
- Increasing Number of Conferences and Events
- POC Tests With Multiplexing Capabilities
Challenges
- Lack of Alignment With Definitive Central Lab Methods
- Inadequate Knowledge About the Use of POC Devices in Professional Settings
- Reluctance Towards Changing Existing Diagnostic Practices
- High Cost of Devices
Emerging Applications of Point-of-Care Testing
- Sepsis Biomarkers
- Stroke Markers
- Thyroid Testing
- Dna Testing
- Endocrine Testing
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Point-of-Care Diagnostics Market, By Product
7 Point-of-Care Diagnostics Market, By Platform
8 Point-of-Care Diagnostics Market, By Prescription Mode
9 Point-of-Care Diagnostics Market, By End User
10 Point-of-Care Diagnostics Market, By Region
11 Competitive Landscape
12 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/s54flj/pointofcarerapi?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Point-of-Care Diagnostics


Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



